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Abstract We report a case of pancreatolithiasis in which
glucose intolerance and malnutrition were significantly
improved after starting oral litholysis therapy (OLT) with
use of trimethadione. A 43-year-old female with multiple
calcified stones in the main and peripheral pancreatic ducts
had experienced recurrent and severe attacks of pain for
7 years (from 21 to28 years of age). Impaired glucose
tolerance was first noted at the age of 32 years. We started
OLT after interventional endoscopic therapy combined
with extracorporeal shock wave lithotripsy failed because
of kink and stenosis of the main pancreatic duct (MPD).
Over the next 9 years, a significant decrease in total pan-
creatic calcified stone volume was shown by computer
analysis of follow-up computed tomography images. Lar-
ger stones completely disappeared without attacks of pain.
In addition, both glucose intolerance and insulin secretion
were significantly ameliorated, followed by improvement
of malnutrition. OLT may induce intraductal decompres-
sion by dissolving stones in the peripheral ducts as well as
the MPD, with resulting preservation of endocrine function
and improvement of malnutrition. Since the present results
were obtained in a single case, further clinical trials are
necessary to evaluate the value of performing OLT under
various conditions to eliminate stones.
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Introduction
Extracorporeal shock wave lithotripsy (ESWL) as well as
endoscopic or surgical therapy are indicated for stones in
the larger pancreatic ducts, particularly the main pancreatic
duct (MPD), and are reported to be effective for immediate
relief of pain. However, many patients show unsatisfactory
response to these treatments, leading to recurrence of
stones during the follow-up period. In addition, their long-
term effects on the recovery of pancreatic dysfunctions
remain uncertain [1–4].
Pancreatic diabetes is an important complication in
patients with chronic calcific pancreatitis and can reduce
quality of life by varying degrees. Overcoming these
problems is a primary concern when managing patients
with chronic calcific pancreatitis, particularly during
the so-called transitional stage. Previously, Noda et al.
[5–7] developed oral litholysis therapy (OLT) with use
of trimethadione (3,5,5-trimethyl-2,4-oxazolidinedione;
TMO) for calcified pancreatic stones and have reported its
usefulness for chemical dissolution of pancreatic stones.
Here, we report a case of chronic calcific pancreatitis, in
which both endocrine dysfunction and malnutrition were
gradually but definitely improved during OLT.
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Case report
A 43-year-old female had suffered from recurrent epigas-
tric and back pain for 7 years (from 21 to 28 years of age).
At the age of 26, a diagnosis of chronic calcific pancreatitis
was made based on findings of hyperamylasemia and
multiple pancreatic calcified stones detected by computed
tomography (CT). Her past medical history was unre-
markable, she was a nonsmoker and did not consume
alcohol, and there was no family history of pancreatic
diseases or diabetes mellitus. No abnormalities were
observed in important organs including the liver, kidneys,
and gastrointestinal tract. Blood levels of parathyroid
hormone in July 1999 (at 28 years of age) were within
normal range [carboxyl-terminal 0.2 (\0.6) ng/ml, intact
24 (14–66) pg/ml, and high-sensitivity 229 (90–270) pg/
ml]. There was no endoscopic abnormality of the papilla of
Vater (Fig. 1a). Endoscopic retrograde pancreatography
revealed kink and stenosis of the MPD in the head of the
pancreas (Fig. 1b), which hampered endoscopic insertion
of a guidewire to the distal MPD. From October 1999 to
November 1999 (at 28 years of age), ESWL was performed
six times against the largest stone in the MPD; however, no
obvious change was observed in its size and shape. In
February 2000 (at 29 years of age), an endoscopic
sphincterotomy was insufficiently performed. Thus, the
patient did not show a response to interventional endo-
scopic retrieval therapy combined with ESWL. Although
hospitalization had been repeated because of recurrent and
severe pain attacks along with temporary hyperamy-
lasemia, the patient has not suffered a pain attack since
1999 (at 28 years of age).
CT scanning performed 3 years later (at 31 years of age)
revealed multiple pancreatic calcified stones in the head
and body, and markedly atrophic pancreatic parenchyma
without calcification in the tail (Fig. 2). Magnetic reso-
nance cholangiopancreatography using 1.5 tesla did not
visualize the MPD and its side branches in the body and
tail. Ultrasonographic images of the pancreatic parenchyma
were indistinct because of multiple calcific stones with
acoustic shadows. Thereafter, we performed follow-up CT
scanning at appropriate intervals to check for parenchymal
changes.
Using computer analysis of obtained CT images, we
attempted to estimate the pancreatic calcified stone vol-
ume. The CT device used during the first period of this
study (July 2002 to December 2005) was a single-slice CT
scanner (X-Vigor Single-Slice CT; Toshiba Medical Sys-
tems Corporation, Japan), while that used during the sec-
ond period (January 2007 to December 2013) was a multi-
slice CT scanner (Asteion Super 4 Edition Multi-Slice CT
4 Data Acquisition System; Toshiba Medical Systems
Corporation). The single-slice CT images were not\3 mm
in size. Thus, in order to obtain consistent follow-up
findings in examinations to determine pancreatic calcified
stone volume, we used 3-mm slice CT scan images pro-
duced from voxel data of the same size obtained by both
devices. We measured the total volume of voxels with a
greater number than the determined threshold in CT images
of pancreatic territories (threshold-positive voxel lesions)
obtained using the image processing and analysis software
package ‘Sync Measure 3D’, which is part of the Image J
software package (Fig. 3). The number of voxels in a CT
image is a unique radiodense unit in the ‘Sync Measure
3D’ package. Data showing each threshold-positive voxel
volume suggested that the detectors of the single-slice CT
device had a lower sensitivity for a high number of voxels
and produced increased noise in images with a low number
of voxels compared to the multi-slice CT device. For sin-
gle-slice CT scanning, the threshold with the highest sig-
nal/noise ratio was 33,006, which was selected as
appropriate for obtaining follow-up data regarding pan-
creatic calcified stone volume. Furthermore, for follow-up
data regarding pancreatic parenchymal volume, we traced
Fig. 1 Endoscopic retrograde
pancreatography images before
OLT. a Endoscopic image of
the papilla of Vater. There was
no abnormal finding.
b Pancreatographic image.
Arrow indicates kink and
stenosis of the MPD in the head
of the pancreas. OLT oral
litholysis therapy
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the outline of the head of the pancreas on the original CT
scan image and measured its volume using the ‘Sync
Measure 3D’ program. Tracing of the body and tail of the
gland was difficult because of the markedly atrophic
change of the parenchyma (Fig. 2b). The head of the
pancreas was defined as the area to the right of the left
border of the superior mesenteric vein.
During the follow-up period, there were no pain attacks
and postprandial plasma glucose (PG) reached the highest
level of 196 mg/dl in July, 2003 (at 32 years of age). The
level of hemoglobin A1c increased from 5.2 % in August
2000 (at 29 years of age) after ESWL to 5.9 %. Further-
more, the initial 75-g oral glucose tolerance test (75-g
OGTT) performed at almost the same time showed
impaired glucose tolerance with insulin resistance accom-
panied by delayed response of immunoreactive insulin
(IRI) and a decreased insulinogenic index (DIRI/DPG) of
0.37 at 30 min (Table 1). In order to prevent progression to
overt diabetes, we started administration of an a-glucosi-
dase inhibitor (aGI) together with double the usual dose of
pancreatic enzyme. However, the second 75-g OGTT
performed in May 3004, 10 months after the start of aGI
(at 33 years of age), showed further deterioration of glu-
cose tolerance and a decrease in insulin secretion (in-
sulinogenic index 0.29) (Table 1). The patient’s body
weight and body mass index (BMI) were lowered to nadirs
of 34.8 kg and 15.2, respectively, in September 2004 (at 33
years of age) (Fig. 4, asterisk). As the patient preferred
aggressive but less invasive treatment to prevent deterio-
ration of glucose tolerance and malnutrition, we selected
OLT with approval of the Ethics Committee of Aichi
Medical University. Before starting treatment, a signed
informed consent form was obtained from the patient in
accordance with the Helsinki Declaration of the World
Medical Association. Before starting OLT in October 2004
(at 33 years of age), no macroscopic steatorrhea was
observed, and there were no abnormalities in blood cell
count, blood chemistry (except the glucose metabolism),
and tumor markers including elastase 1, CA19-9, Dupan-2
and Span 1. TMO was given orally at a starting dose of
0.6 g/day for 3 months, followed by 0.9 g/day, which is the
recommended dose for adults [5]. After starting OLT,
follow-up findings for the threshold-positive voxel volume
demonstrated a gradual and marked decrease, with the
exception of two mild temporal increases, while the
parenchymal volume of the head of the gland showed a
slight decrease (Fig. 5). At 9 years after starting OLT, CT
images obtained in December 2013 demonstrated complete
disappearance of the larger stones in the head and body of
the pancreas (Fig. 6a) and markedly atrophic parenchyma
in the body and tail of the gland, showing almost the same
severity as observed before the treatment (Fig. 6b).
After starting OLT, the PG level gradually decreased,
whereas the IRI level gradually increased during the first
2.5 years (until May 2007) and then decreased with
improvement of the initial secretory response (Table 1). In
April 2011 (6.5 years after starting OLT), peak IRI was
48.6 lU/ml, the same level as observed in the non-obese
healthy Japanese population, and the insulinogenic index
was improved to 0.91 (Table 1). In addition, the patient’s
Fig. 2 Original images from 3-mm slice abdominal CT scans
obtained at 31 (a, b) and 32 (c) years of age (before OLT). a Note
the multiple calcified stones in the head and body of the pancreas.
Arrow indicates superior mesenteric vein. b Arrow indicates markedly
atrophic pancreatic parenchyma without calcification in the tail of the
gland. c Enhanced image showing atrophic parenchyma in the tail of
the gland is more distinguishable (arrow). OLT oral litholysis therapy
Fig. 3 A processed image of original 3-mm slice CT shown in
Fig. 2a using the image processing and analysis component ‘Sync
Measure 3D’ in the Image J software package. In the polygonal lined
area indicating pancreatic territory, white areas indicate lesions
shown by voxels numbering[33,006 (CT radiodense unit used in
‘Sync Measure 3D’). The total size of the white areas in the pancreas
(33,006 threshold-positive lesions) was calculated to measure the
pancreatic calcified stones in each 3-mm slice CT image. OLT oral
litholysis therapy
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appetite gradually increased, which induced an increase in
BMI to 22.8 (April 2014) and the appearance of hyperc-
holesterolemia (Fig. 4). A recent 75-g OGTT (performed in
July 2014) showed an increase in PG at 60 and 90 min in
spite of the increase in IRI (delayed response) (Table 1),
and hemoglobin A1c was 6.0 % in September 2014.
The result of the BT-PABA (N-benzoyl-L-tyrosyl-p-
aminobenzoic acid) test was 85.5 %/6 h (\70.0 %/6 h)
before OLT (in September 2004) and showed a normal or
almost normal level during OLT, ranging from 68.7 %/6r
to 83.4 %/6r.
No laboratory findings suggesting TMO toxicity were
noted in the liver, kidneys, blood, skin, etc. The patient did
not complain of photophobia, which is known to be the
primary adverse effect of TMO. No abnormality was found
in her eyes. At present, the therapy is being continued to
dissolve residual stones, as well as prevent their enlarge-
ment or the recurrence of stones.
Discussion
Pancreatic stones can act as an intraductal barrier to elevate
intraductal pressure, evoke pain [8], and deteriorate pan-
creatic functions. In experimental models of chronic
obstructive pancreatitis, increased pancreatic duct pressure
was found to evoke various kinds of organic and functional
changes of the pancreas, including tissue edema, increase
Fig. 4 Follow-up data for serum total cholesterol (T-Chol, filled
triangle) and body mass index (BMI, filled circle). Minimum BMI
was 15.2 in September 2004 (asterisk), and then gradually increased
after starting OLT. Serum total cholesterol also showed a tendency to
increase and hypercholesterolemia recently appeared. aGI a-glucosi-
dase inhibitor. OLT oral litholysis therapy
Fig. 5 Follow-up data for 33,006 threshold-positive voxel volume in
the pancreas (filled circle) and parenchymal volume of the head of the
pancreas (open square). aGI a-glucosidase inhibitor. OLT oral
litholysis therapy
Table 1 Follow-up data of 75-g oral glucose tolerance test
Date PG (mg/dl) IRI (IU/ml) Insulinogenic index
0 min 30 min 60 min 90 min 120 min 0 min 30 min 60 min 90 min 120 min (DIRI/DPG
at 30 min)
July 2003 99 176 177 171 5.1 33.3 51.9 92.4 0.37
August 2003 Start of aGI
May 2004 92 157 195 198 4.0 23.0 32.8 69.9 0.29
October 2004 Start of OLT
May 2005 93 157 165 156 133 5.0 48.3 61.7 70.6 69.0 0.55
April 2006 98 158 172 150 157 5.1 51.3 81.7 91.0 103.8 0.77
May 2007 92 155 205 173 131 4.0 58.6 90.1 115.0 118.0 0.87
April 2008 92 155 181 149 130 5.2 40.1 54.3 48.7 34.7 0.55
April 2009 95 179 172 122 101 2.8 28.5 42.7 50.6 45.2 0.31
April 2010 90 149 143 160 127 2.5 43.6 39.1 47.1 43.6 0.70
April 2011 93 138 128 141 149 7.1 48.6 29.6 32.2 44.9 0.91
April 2013 99 174 198 199 133 6.5 42.0 65.2 93.0 72.3 0.47
July 2014 102 182 211 221 172 7.1 48.4 53.9 116.0 128.0 0.52
PG plasma glucose, IRI immunoreactive insulin, aGI a-glucosidase inhibitor, OLT oral litholysis therapy
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in fibrous tissue, deletion of acinar cells, reduction in
pancreatic microvascular blood flow (PMBF) [9, 10], and
glucose intolerance in spite of preservation of the islets of
Langerhans [11]. Pancreatic duct decompression in such
experimental models was also found to induce regeneration
of acinar cells and improvements in pancreatic edema,
fibrosis, and PMBF [9, 10], which restore the function of
preserved endocrine cells.
ESWL, as well as endoscopic and surgical therapy, has
been reported to be effective for removal of stones in larger
pancreatic ducts and immediate relief of pain [1–4].
However, these treatments frequently result in poor out-
come for patients with diffuse or multiple stones. A mul-
ticenter study conducted in Japan revealed that the rate of
recurrence after combined ESWL and endoscopic therapy
was 22.0 %, and was especially increased in patients with
MPD stenosis [4]. Their long-term effects on recovery of
pancreatic dysfunctions remain uncertain [1–4]. We think
these therapies have little efficacy against the increasing
number of small stones in peripheral pancreatic ducts,
which cause silent and gradual deterioration of endocrine
and exocrine functions despite the removal of MPD stones.
Other means should be introduced to preserve pancreatic
parenchyma and functions as much as possible by pre-
venting precipitation and growth of calcium carbonate and
dissolving immature or small stones, especially in periph-
eral pancreatic ducts. These effects, if obtained, may also
save patients from recurrent attacks.
This case can be considered as idiopathic chronic pan-
creatitis. Stenosis of the MPD may play an etiological role
in the development of chronic inflammation and calcifi-
cation of concretions. Before starting OLT, this patient had
been in a state of glucose intolerance and malnutrition but
without evidence of definite pancreatic exocrine dysfunc-
tion as shown by steatorrhea and abnormal BT-PABA test.
This indicates that chronic pancreatitis in this patient had
been in the transitional stage and not in the noncompen-
satory stage. Both kink and severe stenosis of the MPD,
which had formed in the head of the pancreas (Fig. 1b),
hampered endoscopic therapy and ESWL. As the findings
of the second OGTT strongly suggested a high risk of
progression to overt diabetes, we applied OLT with use of
TMO as an attempt to preserve pancreatic function or delay
its aggravation. TMO, an older antiepileptic agent that is
rarely used in epileptic patients because more effective
drugs are available, is converted to dimethadione (5,5-
dimethyl-2,4-oxazolidinedione; DMO) by metabolic
demethylation. DMO is a lipid-soluble weak organic acid
with a molecular weight of 129.12 and pKa of 6.13 at
37 C that diffuses rapidly to alkaline fluid compartments
in accordance with pH gradient [12]. Macroautoradiology
using [14C]DMO in the rat revealed significant accumula-
tion of DMO in the pancreas [13]. Furthermore, the non-
dissociated form of DMO diffuses from capillaries to
alkaline pancreatic juice via extracellular space [5] and
dissolves calcium carbonate, a main constituent of pan-
creatic stones, by releasing proton in pancreatic juice [14].
The prior interventional therapies including endoscopic
sphincterotomy and papillary dilatation combined with
ESWL may facilitate the effect of OLT on stone elimina-
tion [7]. In this patient, endoscopic sphincterotomy was
insufficient, and the papilla of Vater was endoscopically
normal (Fig. 1a). To date, we have never experienced
spontaneous dissolution of pancreatic stones, and there is
no evidence to indicate the direct effect of DMO on
endocrine cells related to glucose metabolism. Therefore,
we stress that OLT is responsible for the results obtained in
this patient. The following mechanism can be induced on
referring to the results obtained in experimental models of
chronic obstructive pancreatitis [9–11]. OLT can dissolve
immature or small calcified stones in peripheral ducts as
well as larger ducts, and decompress intraductal pressure.
Fig. 6 Images from 3-mm slice abdominal CT scans obtained in
December 2013, 9 years after starting OLT (at 42 years of age).
a Arrowhead indicates the markedly atrophic parenchyma in the body
of the pancreas. Arrow indicates the superior mesenteric vein. Note
the complete disappearance of larger stones in the head and body of
the gland vizualized before OLT (Fig. 2a). b Arrow indicates
markedly atrophic parenchyma without calcification in the tail of
the gland, showing almost the same severity as observed before OLT
(Fig. 2b). OLT oral litholysis therapy
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These effects can improve organic changes including
pancreatic edema, fibrosis and PMBF, and ameliorate the
malnutrition and dysfunction of preserved endocrine cells.
The most recent result of OGTT in this patient showed
hypersecretion of insulin and delayed response, which is a
pattern of insulin resistance largely attributable to exces-
sive recovery from malnutrition (i.e., the so-called ten-
dency of metabolic syndrome).
Thus, oral administration of TMO shows a steady effect
on calcified stones in the peripheral pancreatic ducts as
well as the MPD, although long-term use of the recom-
mended dose of TMO is needed to dissolve stones and
prevent relapse of stones [5, 6]. In the present case, two
mild temporal increases of threshold-positive volumes
were observed in 3-mm slice CT scan images in spite of a
steady decrease in pancreatic calcified stone volume, which
may have been the result of aggregation or separation of
stones. It is considered that threshold-positive volumes
from 1-mm slice CT scan images can provide more precise
information regarding changes in total and peripheral
pancreatic duct stone volume.
It is generally known that 75-g OTT is extremely useful
for evaluation and follow-up of glucose tolerance. In this
case, test results provided much useful data regarding
changes in PG and insulin secretion. We recommend that
both 75-g OGTT and computer analysis as mentioned
above be applied regardless of the removal therapy utilized
for pancreatic stones.
OLT may elicit a decrease in intraductal pressure by
dissolving stones in peripheral ducts as well as the MPD,
which may have a favorable effect on endocrine function
and contribute to improvement of malnutrition. Since the
present results were obtained in a single case, further
clinical trials are necessary to evaluate the value of per-
forming OLT under various conditions to eliminate stones.
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